Advocacy at a Glance STEVEN GROSSMAN 3/3/17 Advocacy at a Glance STEVEN GROSSMAN 3/3/17 FDA Stakeholders Should Be Very Concerned, But Not Panicked Read More Analysis and Commentary STEVEN GROSSMAN 2/24/17 Analysis and Commentary STEVEN GROSSMAN 2/24/17 There Is No Secret Plan ... And No "Secret Sauce" Either! Read More Advocacy at a Glance STEVEN GROSSMAN 2/24/17 Advocacy at a Glance STEVEN GROSSMAN 2/24/17 HHS Secretary Price Tours FDA and more Read More STEVEN GROSSMAN 2/18/17 STEVEN GROSSMAN 2/18/17 The Alliance Sets It's "Ask" for FY 18 Read More Advocacy at a Glance STEVEN GROSSMAN 2/18/17 Advocacy at a Glance STEVEN GROSSMAN 2/18/17 Uncertain Effects on FDA of Hiring Freeze and more Read More Analysis and Commentary STEVEN GROSSMAN 2/13/17 Analysis and Commentary STEVEN GROSSMAN 2/13/17 Strong Leadership on Resources Essential Read More Advocacy at a Glance STEVEN GROSSMAN 2/13/17 Advocacy at a Glance STEVEN GROSSMAN 2/13/17 FDA’s Status Uncertain Read More Analysis and Commentary STEVEN GROSSMAN 2/3/17 Analysis and Commentary STEVEN GROSSMAN 2/3/17 One Size Still Does Not Fit All Read More Advocacy at a Glance STEVEN GROSSMAN 2/3/17 Advocacy at a Glance STEVEN GROSSMAN 2/3/17 OMB Clarifies Some Details on the President’s Federal Hiring Freeze and more Read More Analysis and Commentary STEVEN GROSSMAN 1/27/17 Analysis and Commentary STEVEN GROSSMAN 1/27/17 The Ramifications of the Federal Hiring Freeze Read More Advocacy at a Glance STEVEN GROSSMAN 1/27/17 Advocacy at a Glance STEVEN GROSSMAN 1/27/17 Trump Era Begins at HHS and FDA and more Read More Analysis and Commentary STEVEN GROSSMAN 1/19/17 Analysis and Commentary STEVEN GROSSMAN 1/19/17 Will Next Monday Be Different Than Today? Read More Advocacy at a Glance STEVEN GROSSMAN 1/19/17 Advocacy at a Glance STEVEN GROSSMAN 1/19/17 Prepping for the New Congress: Macro- and Micro-Budget Considerations for FDA and more Read More Analysis and Commentary STEVEN GROSSMAN 1/13/17 Analysis and Commentary STEVEN GROSSMAN 1/13/17 Advocacy and the "Iron Triangle" of Deficit Reduction Read More Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Sequester May Follow April 28 Expiration of FY 17 CR Read More Analysis and Commentary STEVEN GROSSMAN 1/6/17 Analysis and Commentary STEVEN GROSSMAN 1/6/17 The Speedy Appointment of a New Commissioner? Read More Advocacy at a Glance STEVEN GROSSMAN 1/6/17 Advocacy at a Glance STEVEN GROSSMAN 1/6/17 Wishing Everyone a Happy and Healthy New Year. Read More Analysis and Commentary STEVEN GROSSMAN 12/16/16 Analysis and Commentary STEVEN GROSSMAN 12/16/16 Time for a Deep Breath Before the New Year Begins Read More Advocacy at a Glance STEVEN GROSSMAN 12/16/16 Advocacy at a Glance STEVEN GROSSMAN 12/16/16 FY 17 Continuing Resolution to Run Through April 28, 2017 Read More Analysis and Commentary STEVEN GROSSMAN 12/9/16 Analysis and Commentary STEVEN GROSSMAN 12/9/16 Setting the Advocacy Stage for FY 18 and After Read More Newer Posts Older Posts
Advocacy at a Glance STEVEN GROSSMAN 3/3/17 Advocacy at a Glance STEVEN GROSSMAN 3/3/17 FDA Stakeholders Should Be Very Concerned, But Not Panicked Read More
Analysis and Commentary STEVEN GROSSMAN 2/24/17 Analysis and Commentary STEVEN GROSSMAN 2/24/17 There Is No Secret Plan ... And No "Secret Sauce" Either! Read More
Advocacy at a Glance STEVEN GROSSMAN 2/24/17 Advocacy at a Glance STEVEN GROSSMAN 2/24/17 HHS Secretary Price Tours FDA and more Read More
Advocacy at a Glance STEVEN GROSSMAN 2/18/17 Advocacy at a Glance STEVEN GROSSMAN 2/18/17 Uncertain Effects on FDA of Hiring Freeze and more Read More
Analysis and Commentary STEVEN GROSSMAN 2/13/17 Analysis and Commentary STEVEN GROSSMAN 2/13/17 Strong Leadership on Resources Essential Read More
Advocacy at a Glance STEVEN GROSSMAN 2/13/17 Advocacy at a Glance STEVEN GROSSMAN 2/13/17 FDA’s Status Uncertain Read More
Analysis and Commentary STEVEN GROSSMAN 2/3/17 Analysis and Commentary STEVEN GROSSMAN 2/3/17 One Size Still Does Not Fit All Read More
Advocacy at a Glance STEVEN GROSSMAN 2/3/17 Advocacy at a Glance STEVEN GROSSMAN 2/3/17 OMB Clarifies Some Details on the President’s Federal Hiring Freeze and more Read More
Analysis and Commentary STEVEN GROSSMAN 1/27/17 Analysis and Commentary STEVEN GROSSMAN 1/27/17 The Ramifications of the Federal Hiring Freeze Read More
Advocacy at a Glance STEVEN GROSSMAN 1/27/17 Advocacy at a Glance STEVEN GROSSMAN 1/27/17 Trump Era Begins at HHS and FDA and more Read More
Analysis and Commentary STEVEN GROSSMAN 1/19/17 Analysis and Commentary STEVEN GROSSMAN 1/19/17 Will Next Monday Be Different Than Today? Read More
Advocacy at a Glance STEVEN GROSSMAN 1/19/17 Advocacy at a Glance STEVEN GROSSMAN 1/19/17 Prepping for the New Congress: Macro- and Micro-Budget Considerations for FDA and more Read More
Analysis and Commentary STEVEN GROSSMAN 1/13/17 Analysis and Commentary STEVEN GROSSMAN 1/13/17 Advocacy and the "Iron Triangle" of Deficit Reduction Read More
Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Sequester May Follow April 28 Expiration of FY 17 CR Read More
Analysis and Commentary STEVEN GROSSMAN 1/6/17 Analysis and Commentary STEVEN GROSSMAN 1/6/17 The Speedy Appointment of a New Commissioner? Read More
Advocacy at a Glance STEVEN GROSSMAN 1/6/17 Advocacy at a Glance STEVEN GROSSMAN 1/6/17 Wishing Everyone a Happy and Healthy New Year. Read More
Analysis and Commentary STEVEN GROSSMAN 12/16/16 Analysis and Commentary STEVEN GROSSMAN 12/16/16 Time for a Deep Breath Before the New Year Begins Read More
Advocacy at a Glance STEVEN GROSSMAN 12/16/16 Advocacy at a Glance STEVEN GROSSMAN 12/16/16 FY 17 Continuing Resolution to Run Through April 28, 2017 Read More
Analysis and Commentary STEVEN GROSSMAN 12/9/16 Analysis and Commentary STEVEN GROSSMAN 12/9/16 Setting the Advocacy Stage for FY 18 and After Read More
